Helvica Pharma Announces Breakthrough in Oncology Research Trials

ZURICH, SWITZERLAND — Helvica Pharma today announced highly positive topline results from its global Phase III clinical trials evaluating the safety and efficacy of H-429, an investigational targeted therapy for patients with advanced stage oncology conditions.

The trial, which enrolled over 3,000 patients across 45 countries, met both its primary and secondary endpoints. H-429 demonstrated a statistically significant and clinically meaningful improvement in overall survival rates compared to the current standard of care.

"These results represent a watershed moment for patients and our research teams," said Dr. Elena Rostova, Chief Medical Officer at Helvica Pharma. "We are working closely with global regulatory authorities to expedite the review process and bring this life-saving treatment to patients as quickly as possible." Helvica plans to submit regulatory filings in the US and Europe by the end of the current fiscal quarter.